Sign Up to like & get
recommendations!
1
Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.287
Abstract: demonstrate that the pembrolizumab Q6W scheme could generate a cost savings of V 1.2, V 2.2 and 3.0 million for 1,000 patients if compared with pembrolizumab Q3W, nivolumab and ipilimumab respectively. On average, 40% of…
read more here.
Keywords:
wait policy;
pcn150 watch;
cost;
policy versus ... See more keywords